Reports
Sale
Global Gonorrhea Treatment Market Share, Size, Trends, Analysis, Growth, Forecast: By Indication Type: Uncomplicated Gonococcal Infection, Gonococcal Arthritis, Gonococcal Meningitis and Endocarditis, Others; By Drug Category; By Therapeutics; By Diagnosis Methods; By Route of Administration; Regional Analysis; Supplier Landscape; 2024-2032
Global Gonorrhea Treatment Market Outlook
The global gonorrhea treatment market was estimated to be worth USD 1.48 billion in 2023. The market is likely to grow at a rate of 4.7% in the forecasted period 2024-2032. Within this growth rate, the market value is estimated to reach about USD 2.24 billion by 2032. The market is primarily driven by the increased prevalence of sexually transmitted infections and the expected launch of novel therapies.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Gonorrhea Treatment Market Insights: Causes, Symptoms, Diagnosis, Treatment, and Segmentation
Gonorrhea is a very common sexually transmitted infection caused by the bacterium Neisseria gonorrheae. The bacteria enter through different modes, such as anus, mouth, vagina, and penis. The gonorrhea is mainly spread through sexual fluids such as semen and vaginal fluid. Gonorrhea is caused by oral sex, intercourse, anal sex, or sharing sex toys with the infected person.
Gonorrhea is the second most common sexually transmitted infection, with around 1.14 million new gonorrhea infections being diagnosed in the United States every year. Most of the infections occur in people of the age group 15-24 years.
The gonorrheal symptoms vary in men and women and depend on the severity of the disease. The common symptoms witnessed in women are increased vaginal discharge, lower abdominal pain, irregular bleeding between periods, and sexual intercourse pain.
The symptoms reported in men are white or yellow penis discharge, testicular pain, severe pain and burning. The common signs and symptoms of all genders are itchy feeling, soreness, trouble swallowing, itching, anal discharge, and poop difficulty.
The diagnosis of gonorrhea is done by performing a pelvic exam, testing a fluid sample from the penis, and urine sample analysis. The treatment is primarily done through antibiotics and other medications. Palliative care has been an important therapeutic intervention in the management of gonorrhea.
According to the global gonorrhea treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Indication Type
- Uncomplicated Gonococcal Infection
- Gonococcal Arthritis
- Gonococcal Meningitis and Endocarditis
- Others
Market Breakup by Drug Category
- Macrolide Antibiotics
- Azithromycin
- Third-Generation Cephalosporins
- Cefixime
- Cefotaxime
- Ceftizoxime
- Ceftriaxone
- Cetriaxone
- Tetracycline Antibiotics
- Doxycycline
- Fluoroquinolones Antibiotics
- Gemifloxacin
- Aminoglycosides
- Gentamicin
- Aminocyclitols
- Spectinomycin
- Others
Market Breakup by Therapeutics
- Monotherapy
- Dual Therapy
- Others
Gonorrhea Treatment Market Breakup by Diagnosis Methods
- Nucleic Acid Amplification
- Gram Stain
- Enzyme-linked Immunosorbent Assay
- Gonorrhea Culture and Rapid Test
- Others
Market Breakup by Route of Administration
- Oral
- Injectable
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Scenario
The growth of the gonorrhea treatment market is primarily driven by the rising prevalence and incidence of gonorrhea, the introduction of national screening programs and growing awareness among the general population.
According to the Centres for Disease Control and Prevention, nearly 700,000 novel cases of gonorrhea are diagnosed annually across the world. Thus, with the growing incidence of sexually transmitted infections, the market is anticipated to grow positively during the forecast period.
The introduction of technologically advanced tools for diagnosing bacterial growth and the concentration of lesions is anticipated to attribute to the increased patient pool. This has led to the increased demand for novel therapeutics, which will bolster the growth of the market.
Additionally, with the increasing resistance to the available antibiotics, there is a need for the discovery of novel medications. This is expected to aid the expansion of the gonorrhea treatment market owing to the novel product approvals and launches. Further, the growing research and developmental activities and the rising number of prescription drugs are fuelling the market growth.
Recent Market Trends: Based on Therapy and Region
Dual therapy is anticipated to dominate the market during the forecast period due to its rising adoption and better therapeutic efficacy than monotherapy. Additionally, the dual therapy of azithromycin and ceftriaxone is considered a first-line treatment for the management of gonorrhea.
North America is anticipated to hold the largest share of the gonorrhea treatment market. This growth can be attributed to the advanced healthcare infrastructure and easy accessibility to novel technologies. Further, the increasing disease burden and the growing number of mergers and acquisitions among the key players are expected to augment the market growth in this region.
Therapeutic Landscape
The therapeutic interventions incorporated in gonorrhea management depend on the age and gender of the patient. The treatment regimen generally involves the administration of antibiotics that aid in the slower progression of the disease by inhibiting the bacterial growth.
Treatment for Adults and Children
The rising cases of gonorrhea are leading to the growth of the gonorrhea treatment market. The treatment for adult gonorrhea patients involves the treatment with specific antibiotics that possess bacterial inhibition and thus, help in disease management. The commonly used antibiotic, ceftriaxone is being given as an injection in combination with oral azithromycin for the first-line treatment of asymptomatic gonorrhea. In case of intolerance to cephalosporin antibiotics, the combination of injectable gentamicin with oral azithromycin is considered.
Gonorrhea treatment should be received by both partners, irrespective of whether the partner is exhibiting any symptoms or not. The same diagnostic and therapeutic regimen is followed for both partners to prevent the disease in the future.
The treatment for new-born babies who had gotten the infection through their mothers is also diagnosed with the help of antibiotics.
Despite the availability of novel antibiotics, new strains of the bacteriae are developing resistance against these antibiotics, and hence, preventative care is essential to eradicate this problem. Safe sex needs to be practised from avoiding gonorrhea again and again in the further years.
Clinical Trials Landscape of the Gonorrhea Treatment Market
Over the last few decades, there has been a discovery of novel antibiotics for the treatment of symptomatic and asymptomatic gonorrhea. These medications can be administered orally or parenterally.
However, with the rapid mutations, the bacterial strains keep mutating and eventually develop resistance against the antibiotics. Therefore, clinical researchers are tremendously working on developing novel therapeutic agents that could aid in disease management.
Further, the treatment does not ensure the recurrence of the disease, hence scientists are also conducting clinical trials for the discovery of a gonorrheal vaccine that will act as a preventative measure and will prevent the disease occurrence.
Undergoing Clinical Trials For Novel Antibiotics and Vaccines in the Gonorrhea Treatment Market
Evoform Biosciences, a key market player is conducting the EVOGUARD clinical trials for the novel agent, EVO100, for the management and prevention of gonorrhea in women.
A dutch biotechnological company, Intravacc, has also initiated the Phase I clinical trials for its novel vaccine, NGoXIM. This vaccine has been developed by incorporating the outer membrane vesicles that possess immune-stimulating properties. The vaccine is expected to show a promising effect in the treatment of gonorrhea.
Several diagnostic systems are also under investigation, and once approved can aid in the faster and more accurate detection of gonorrhea disease. Lucina Health, a major pharmaceutical company, is testing its novel assay systems that are expected to augment the market growth. The investigational instrument incorporates both Chlamydia trachomatis and Neisseria gonorrheae assays that will provide the diagnosis with an overall accuracy of nearly 98 per cent.
These novel targeted therapies seem to grab the attention of key companies and investors, which will directly influence the development of this sector. This will help enable patient access and the growth of the market.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the gonorrhea treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Hologic, Inc.
- Danaher
- BD (Becton, Dickinson and Company)
- Teligent
- GSK plc
- Abbott
- Lupin Pharmaceuticals, Inc.
- Novartis AG
- Bayer AG
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication Type |
|
| Breakup by Drug Category |
|
| Breakup by Therapeutics |
|
| Breakup by Diagnosis Methods |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Gonorrhea Disease Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Gonorrhea Treatment Market
6.1 Global Gonorrhea Treatment Market Overview
6.2 Global Gonorrhea Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Gonorrhea Treatment Market Historical Value (2017-2023)
6.2.1.2 Global Gonorrhea Treatment Market Forecast Value (2024-2032)
6.2.2 Global Gonorrhea Treatment Market by Indication Type
6.2.2.1 Market Overview
6.2.2.1.1 Uncomplicated Gonococcal Infection
6.2.2.1.2 Gonococcal Arthritis
6.2.2.1.3 Gonococcal Meningitis and Endocarditis
6.2.2.1.4 Others
6.2.3 Global Gonorrhea Treatment Market by Drug Category
6.2.3.1 Market Overview
6.2.3.1.1 Macrolide Antibiotics
6.2.3.1.1.1 Azithromycin
6.2.3.1.2 Third-Generation Cephalosporins
6.2.3.1.2.1 Cefixime
6.2.3.1.2.2 Cefotaxime
6.2.3.1.2.3 Ceftizoxime
6.2.3.1.2.4 Ceftriaxone
6.2.3.1.2.5 Cetriaxone
6.2.3.1.3 Tetracycline Antibiotics
6.2.3.1.3.1 Doxycycline
6.2.3.1.4 Fluoroquinolones Antibiotics
6.2.3.1.4.1 Gemifloxacin
6.2.3.1.5 Aminoglycosides
6.2.3.1.5.1 Gentamicin
6.2.3.1.6 Aminocyclitols
6.2.3.1.6.1 Spectinomycin
6.2.3.1.7 Others
6.2.4 Global Gonorrhea Treatment Market by Therapeutics
6.2.4.1 Market Overview
6.2.4.1.1 Monotherapy
6.2.4.1.2 Dual Therapy
6.2.4.1.3 Others
6.2.5 Global Gonorrhea Treatment Market by Diagnosis Methods
6.2.5.1 Market Overview
6.2.5.1.1 Nucleic Acid Amplification
6.2.5.1.2 Gram Stain
6.2.5.1.3 Enzyme-linked Immunosorbent Assay
6.2.5.1.4 Gonorrhea Culture and Rapid Test
6.2.5.1.5 Others
6.2.6 Global Gonorrhea Treatment Market by Route of Administration
6.2.6.1 Market Overview
6.2.6.1.1 Oral
6.2.6.1.2 Injectable
6.2.6.1.3 Others
6.2.7 Global Gonorrhea Treatment Market by Region
6.2.7.1 Market Overview
6.2.7.1.1 North America
6.2.7.1.2 Europe
6.2.7.1.3 Asia Pacific
6.2.7.1.4 Middle East & Africa
6.2.7.1.5 Latin America
6.2.8 North America
6.2.8.1 Historical Trend (2017-2023)
6.2.8.2 Forecast Trend (2024-2032)
6.2.8.3 Break Up by Country
6.2.8.3.1 United States of America
6.2.8.3.2 Canada
6.2.9 Europe
6.2.9.1 Historical Trend (2017-2023)
6.2.9.2 Forecast Trend (2024-2032)
6.2.9.3 Break Up by Country
6.2.9.3.1 United Kingdom
6.2.9.3.2 Germany
6.2.9.3.3 France
6.2.9.3.4 Italy
6.2.9.3.5 Others
6.2.10 Asia Pacific
6.2.10.1 Historical Trend (2017-2023)
6.2.10.2 Forecast Trend (2024-2032)
6.2.10.3 Break Up by Country
6.2.10.3.1 China
6.2.10.3.2 Japan
6.2.10.3.3 India
6.2.10.3.4 ASEAN
6.2.10.3.5 Australia
6.2.10.3.6 Others
6.2.11 Latin America
6.2.11.1 Historical Trend (2017-2023)
6.2.11.2 Forecast Trend (2024-2032)
6.2.11.3 Break Up by Country
6.2.11.3.1 Brazil
6.2.11.3.2 Argentina
6.2.11.3.3 Mexico
6.2.11.3.4 Others
6.2.12 Middle East and Africa
6.2.12.1 Historical Trend (2017-2023)
6.2.12.2 Forecast Trend (2024-2032)
6.2.12.3 Break Up by Country
6.2.12.3.1 Saudi Arabia
6.2.12.3.2 United Arab Emirates
6.2.12.3.3 Nigeria
6.2.12.3.4 South Africa
6.2.12.3.5 Others
7 Current Scenario Evaluation and Regulatory Framework
7.1 Emerging Therapies and Clinical Trials
7.2 Patent Landscape
7.2.1 Patent Overview
7.2.1.1 Patent Status and Expiry
7.2.1.2 Timelines from Drug Development to Commercial Launch
7.2.1.3 New Drug Application
7.2.1.3.1 Documentation and Approval Process
7.3 Cost of Treatment
7.4 Regulatory Framework
7.4.1 Regulatory Overview
7.4.1.1 US FDA
7.4.1.2 EU EMA
7.4.1.3 INDIA CDSCO
7.4.1.4 JAPAN PMDA
7.4.1.5 Others
8 Challenges & Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Global Gonorrhea Treatment Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives & Trends
9.7 Value Chain Analysis
10 Supplier Landscape
10.1 Hologic, Inc.
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 Danaher
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 BD (Becton, Dickinson and Company)
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 Teligent
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 GSK plc
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Abbott
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 Lupin Pharmaceuticals, Inc.
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Novartis AG
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Bayer AG
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 F. Hoffmann-La Roche Ltd
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
10.11 Pfizer Inc.
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.11.5 Certifications
11 Recommendations and Discussion
12 Global Gonorrhea Treatment Drugs Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket
*Additional insights provided are customizable as per client requirements.
Key Questions Answered in the Report
The market is primarily driven by the rising prevalence of sexually transmitted disorders, increasing research and developmental activities, raising awareness, novel product launches and approvals, and favouring government initiatives.
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America is anticipated to hold a significant share of the market during the forecast period.
Based on the drug type, the market is segmented into macrolide antibiotics, third-generation cephalosporins, tetracycline antibiotics, fluoroquinolones antibiotics, aminoglycosides, and aminocyclitols, among others.
Based on the indication type, the market is bifurcated into uncomplicated gonococcal infection, gonococcal arthritis, gonococcal meningitis and endocarditis, among others.
Based on the therapy type, the market is divided into monotherapy and dual therapy, among others.
Based on the route of administration, the market is categorised into oral, parenteral, topical, and others.
Based on the diagnosis type, the market is divided into nucleic acid amplification, gram stain, enzyme-linked immunosorbent assay, gonorrhea culture and rapid test, among others.
The key companies involved in the market are Hologic, Inc., Danaher, BD (Becton, Dickinson and Company), Teligent, GSK plc, Abbott, Lupin Pharmaceuticals, Inc., Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd, and Pfizer Inc., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER